Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma

Overview of attention for article published in Cancer Research Communications, February 2025

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (56th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

bluesky: 2 Bluesky users

Readers on

mendeley: 9 Mendeley

So far, Altmetric has seen 6 X posts from 4 X users, with an upper bound of 5,619 followers.

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma https://t.co/Tr5l5qylix

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma https://t.co/jeXzKX89Sr #ScientiaVH

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma https://t.co/ycn9Q70GKl #hvhebron #onco [Text complet]

La combinación de Simlukafusp Alfa y Pembrolizumab muestra resultados prometedores en tratamiento de melanoma avanzado. ¿Cómo afectará esto a futuras terapias? 🤔 #InvestigarMás https://t.co/XXeBXXRVyz

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.